Collection and storage of red blood cells with anticoagulant and additive solution with a physiologic pH.
BACKGROUND
A donation of whole blood is most commonly collected in acidic citrate-phosphate-dextrose (CPD) variants with pH 5.2 to 6.2 as anticoagulants. Previously, we have shown that the initial pH after red blood cell (RBC) preparation can have an effect on RBCs during storage. First, we investigated the effect of the pH of the anticoagulant on RBCs. Second, we investigated the possibility of decreasing the pH of our new additive solution (AS) phosphate-adenine-glucose-guanosine-gluconate-mannitol (PAGGGM) from pH 8.2 to 7.4 in combination with an anticoagulant with a physiologic pH.


METHODS
Whole blood was collected in CPD (pH 5.6) or trisodiumcitrate (TNC; pH 7.4), and leukoreduced units were prepared using saline-adenine-glucose-mannitol as AS. Second, whole blood was collected in TNC (pH 7.4), and leukoreduced units were prepared using PAGGGM (pH 7.4) or PAGGGM (pH 8.2) as AS. During cold storage, several in vitro characteristics were analyzed.


RESULTS
In agreement with our previous findings, the initial pH of whole blood has an effect during storage of RBCs. In the second part we show that there are no differences between PAGGGM (pH 7.4) and PAGGGM (pH 8.2) units when an anticoagulant with a physiologic pH was used.


CONCLUSIONS
These results indicate that the pH of the anticoagulant used during whole blood collection has an effect during storage of RBCs. When an anticoagulant with a physiologic pH is used during whole blood collection, the pH of PAGGGM can be decreased to physiologic levels, while maintaining adenosine triphosphate and 2,3-diphosphoglycerate levels.
Department of Blood Cell Research, Sanquin Research, Amsterdam, The Netherlands.
Patrick
P
Burger
Herbert
H
Korsten
Arthur J
AJ
Verhoeven
Dirk
D
de Korte
Robin
R
van Bruggen
D000225:Adenine / Q000494:pharmacology; D000925:Anticoagulants / Q000494:pharmacology*; D001793:Blood Preservation / Q000009:adverse effects / Q000379:methods*; D001800:Blood Specimen Collection / Q000009:adverse effects / Q000379:methods*; D002951:Citrates / Q000494:pharmacology; D004912:Erythrocytes / Q000737:chemistry / Q000166:cytology / Q000187:drug effects* / Q000502:physiology; D005240:Feasibility Studies; D005942:Gluconates / Q000494:pharmacology; D005947:Glucose / Q000494:pharmacology; D006151:Guanosine / Q000494:pharmacology; D006801:Humans; D006863:Hydrogen-Ion Concentration; D066298:In Vitro Techniques; D008353:Mannitol / Q000494:pharmacology; D019188:Organ Preservation Solutions / Q000737:chemistry / Q000494:pharmacology*; D010710:Phosphates / Q000494:pharmacology; D013997:Time Factors
D000925:Anticoagulants; D002951:Citrates; D005942:Gluconates; D019188:Organ Preservation Solutions; D010710:Phosphates; C514290:trisodium citrate; D006151:Guanosine; D008353:Mannitol; C007077:citrate phosphate dextrose; D005947:Glucose; D000225:Adenine; C030691:gluconic acid